Word For Health

word4health.com– This time we will talk about cancer treatment. There are still many people the wrong assumption, especially in the stages of cancer treatment. Actually, when the patient had undergone surgical removal of cancer once, but still there are phases that must be done afterward.

We all know that cancer cells can invade tissues and blood as well. especially if it is carried by the flow of blood. Cancer can take root, and roots must be aware that a patient who has already done the first time removing the cancer.

Chemotherapy is a familiar thing in the world of cancer. Currently the latest breakthrough came from a cancer drug. Nimotuzumab is the newest cancer drugs are one of those “targeted therapy”. The new drug was removed, and the marketing authorization approval from drug regulatory agencies and food.

Nimotuzumab works very selective by making specific substances in the body that play a role in the process of cancer growth as a “target”. This is what distinguishes between the treatment of other cancers with Nimatuzumab.For therapy side effects for patients will be lighter than conventional therapies kinds of chemotherapy. Generally, patients will not experience hair loss, vomiting, or decreased white blood cells.

Epidermal Gowth Factor Receptor

Target nimotuzumab, a monoclonal antibody, is the Epidermal Growth Factor Receptor (EGFR). Presence of EGFR in the cancer patient’s body in excess amount to be bad sign that the disease suffered by cancer patients more quickly deteriorated and administration of chemotherapy and radiotherapy to be very ineffective. this causes the cancer patient life expectancy becomes shorter.

The discovery of EGFR targeted therapy against these opportunities more successful cancer therapy of patients with increased life expectancy, and quality of life of cancer patients.

From various studies that have been executed is known that EGFR is common in patients with head and neck cancer, kanke colon, lung cancer, glioma (brain cancer satujenis one), cervical cancer, breast cancer, and other solid cancers.
Therefore Nimatuzumab targeted therapy has the potential to treat cancer.